A Bioelectronic Medicine Company
advancing the treatment of autoimmune diseases.

About Us
Boomerang Medical is a women-led bioelectronic medicine company on a mission to disrupt the treatment of autoimmune diseases. The company is developing a bioelectric neuromodulation technology, which has been granted Breakthrough Device Designation by the FDA for the treatment of Crohn's disease and ulcerative colitis. The technology is currently being evaluated in an FDA-approved clinical trial studying ulcerative colitis at leading IBD centers in the US.
Our Focus
Inflammatory Bowel Disease (IBD) is one of the most debilitating autoimmune diseases, affecting millions globally. Living with IBD impacts not just physical health, but also work, relationships, and well-being. Current treatments include medications and surgery, but the complexity of the condition means that there is always room for innovative approaches.
What if the next big leap in managing IBD is already hardwired into our bodies? That's the question propelling our focus on neuromodulation, a promising frontier in bioelectronic medicine.
Boomerang Medical is dedicated to promoting IBD awareness and education. We are proud to be a member of the Crohn’s & Colitis Foundation's Corporate Circle.
Boomerang Medical is headquartered in the heart of Silicon Valley on the campus of El Camino Hospital in Mountain View, California. We are proud to be a Company–In-Residence at the prestigious Fogarty Innovation incubator–the only healthcare-focused incubator of its kind in the US–giving us access to the brightest minds and expertise in the medical technology industry.
Meet the Team
Board of Directors + Advisors
Boomerang Medical is proud to be a portfolio company of
Arboretum Ventures and Hatteras Venture Partners, as well as a
Company-In-Residence at Fogarty Innovation.
Heather Simonsen
Boomerang Medical
President & CEO
Andrew Cleeland
Fogarty Innovation
Chief Executive Officer
Tom Shehab, MD
Arboretum Ventures
Managing Partner
Gayle Kuokka
Fogarty Innovation
Chief Financial Officer
Jeff Terrell
Hatteras Venture Partners
General Partner
John Morriss
Fogarty Innovation
Director of Innovation Acceleration
Scientific Advisors
Peter Irving, MA, MD, FRCP
Co-PI of BOOM-IBD2 Pivotal Trial
Guy’s and St Thomas’ NHS Foundation Trust
Consultant Gastroenterologist
​
Kings College London
Professor of Inflammatory Bowel Disease
Corey A. Siegel, MD, MS
Chief Scientific Advisor
Dartmouth-Hitchcock Medical Center
Section Chief of Gastroenterology and Hepatology, Co-Director of the IBD Center
Edward Barnes, MD, MPH
Co-PI of BOOM-IBD2 Pivotal Trial
University of North Carolina at Chapel Hill
Associate Professor of Medicine,
Co-Director of Multidisciplinary IBD Center
Laura Raffals, MD
Scientific Advisory Board Member
Mayo Clinic
Professor of Medicine, Department of Medicine Associate Chair of Faculty Development, Vice Chair of the Division of Gastroenterology & Hepatology
​